Special Issue "The Story of Successful Drugs and Recent FDA-Approved Molecules"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: 31 December 2019

Special Issue Editors

Guest Editor
Dr. Jean Jacques Vanden Eynde

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium
Website | E-Mail
Phone: 3204790134085
Interests: heterocycles; microwave-induced synthesis; medicinal chemistry; green chemistry
Guest Editor
Prof. Dr. Klaus Kopka

Division of Radiopharmaceutical Chemistry, Research Program Imaging and Radiooncology, German Cancer Research Center (dkfz), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
Website | E-Mail
Interests: radiopharmaceutical sciences; labeling chemistry; medicinal chemistry; PET tracers; radiopharmaceuticals for diagnostics and endoradiotherapy; small molecules; peptides; antibodies and derivatives thereof
Guest Editor
Prof. Dr. Maria Emília De Sousa

1. Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal 2. Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR/CIMAR), Universidade do Porto, Terminal de Cruzeiros do Porto de Leixões, Avenida General Norton de Matos, S/N 4450-208 Matosinhos, Portugal
Website | E-Mail
Interests: medicinal chemistry; organic synthesis; heterocycles, P-glycoprotein; anticancer; anticoagulants; chiral drugs; marine natural products
Guest Editor
Dr. Annie Mayence

Formerly professor at the Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium
Website | E-Mail
Interests: medicinal chemistry; organic synthesis; parasitic diseases; orphan drugs
Guest Editor
Prof. Dr. Joachim Jose

PharmaCampus Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Corrensstr. 48, 48149, Muenster, Germany
Website | E-Mail
Interests: autodisplay; assay development and inhibitor testing; whole cell biocatalysts for synthesis of drugs and building blocks; directed evolution of enzyme inhibitors and biocatalysts; biosensor development and diagnostic tools
Guest Editor
Dr. Guangshun Wang

Department of Pathology & Microbiology University of Nebraska Medical Center, USA
Website | E-Mail
Interests: host defense antimicrobial peptides; structural bioinformatics; biomolecular NMR

Special Issue Information

Dear Colleagues,

In 2018, the FDA approved 59 novel drugs, a record high, demonstrating the vigor of pharmaceutical industry and associated research groups. Small molecules were the most represented entities among the approvals, but there is an increasing number of antibodies and oligonucleotides on the medical market. Interestingly, there is a growing interest in the development of orphan drugs and the treatment of orphan diseases.

The aim of this Special Issue is to offer to our readers short but comprehensive and updated reviews on compounds recently approved by the FDA and drugs attracting particular attention because of their success.

Dr. Jean Jacques Vanden Eynde
Prof. Dr. Klaus Kopka
Prof. Dr. Maria Emília De Sousa
Dr. Annie Mayence
Prof. Dr. Joachim Jose
Dr. Guangshun Wang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibody
  • aptamer
  • oligonucleotide
  • orphan disease
  • orphan drug
  • peptide
  • small molecule

Published Papers (4 papers)

View options order results:
result details:
Displaying articles 1-4
Export citation of selected articles as:

Review

Jump to: Other

Open AccessReview Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
Pharmaceuticals 2019, 12(2), 62; https://doi.org/10.3390/ph12020062 (registering DOI)
Received: 17 March 2019 / Revised: 16 April 2019 / Accepted: 18 April 2019 / Published: 20 April 2019
PDF Full-text (792 KB) | HTML Full-text | XML Full-text
Abstract
One of the major factors contributing to HIV-1 drug resistance is suboptimal adherence to combination antiretroviral therapy (cART). Currently, recommended cART for HIV-1 treatment is a three-drug combination, whereas the pre-exposure prophylaxis (PrEP) regimens consist of one or two antivirals. Treatment regimens require [...] Read more.
One of the major factors contributing to HIV-1 drug resistance is suboptimal adherence to combination antiretroviral therapy (cART). Currently, recommended cART for HIV-1 treatment is a three-drug combination, whereas the pre-exposure prophylaxis (PrEP) regimens consist of one or two antivirals. Treatment regimens require adherence to a once or twice (in a subset of patients) daily dose. Long-acting formulations such as injections administered monthly could improve adherence and convenience, and thereby have potential to enhance the chances of expected outcomes, although long-lasting drug concentrations can also contribute to clinical issues like adverse events and development of drug resistance. Globally, two long-acting antivirals have been approved, and fifteen are in clinical trials. More than half of investigational long-acting antivirals target HIV-1 reverse transcriptase (HIV-1 RT) and/or integrase (HIV-1 IN). Here, we discuss the status and potential of long-acting inhibitors, including rilpivirine (RPV), dapivirine (DPV), and 4-ethynyl-2-fluoro-2-deoxyadenosine (EFdA; also known as MK-8591), which target RT, and cabotegravir (CAB), which targets IN. The outcomes of various clinical trials appear quite satisfactory, and the future of long-acting HIV-1 regimens appears bright. Full article
(This article belongs to the Special Issue The Story of Successful Drugs and Recent FDA-Approved Molecules)
Figures

Figure 1

Open AccessReview 2018 FDA Tides Harvest
Pharmaceuticals 2019, 12(2), 52; https://doi.org/10.3390/ph12020052
Received: 12 March 2019 / Revised: 3 April 2019 / Accepted: 3 April 2019 / Published: 5 April 2019
PDF Full-text (877 KB) | HTML Full-text | XML Full-text
Abstract
In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, [...] Read more.
In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics. Full article
(This article belongs to the Special Issue The Story of Successful Drugs and Recent FDA-Approved Molecules)
Figures

Figure 1

Other

Jump to: Review

Open AccessBrief Report Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
Pharmaceuticals 2019, 12(2), 63; https://doi.org/10.3390/ph12020063 (registering DOI)
Received: 10 March 2019 / Revised: 16 April 2019 / Accepted: 18 April 2019 / Published: 21 April 2019
PDF Full-text (553 KB)
Abstract
Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by [...] Read more.
Omadacycline (Nuzyra®) is a new aminomethylcycline, approved by the U. S. Food and Drug Administration in 2018, as a tetracycline antibacterial. It can be used in community-acquired pneumonia and in acute bacterial skin and skin-structure infections. It was developed and is commercialized by Paratek Pharmaceuticals. It is a semisynthetic compound, derived from minocycline, capable of evading widely distributed efflux and target protection antibacterial resistance mechanisms and has demonstrated activity in a broad spectrum of bacteria. Full article
(This article belongs to the Special Issue The Story of Successful Drugs and Recent FDA-Approved Molecules)
Open AccessBrief Report Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
Pharmaceuticals 2019, 12(1), 37; https://doi.org/10.3390/ph12010037
Received: 18 February 2019 / Revised: 5 March 2019 / Accepted: 10 March 2019 / Published: 12 March 2019
PDF Full-text (1010 KB) | HTML Full-text | XML Full-text
Abstract
In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes. [...] Read more.
In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes. Full article
(This article belongs to the Special Issue The Story of Successful Drugs and Recent FDA-Approved Molecules)
Figures

Figure 1

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top